A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
A Single-arm, Open-label, Multicenter, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Sponsor: Akeso
Terminated
Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop study.
A PHASE2 clinical study on MSI-H/dMMR Solid Tumor, this trial is terminated or withdrawn. The trial is conducted by Akeso and has accumulated 6 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Oct 2022 — Nov 2022 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2022 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akeso
- Akeso Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .